Does suppression of IL-4 synthesis by aspirin explain the therapeutic benefit of aspirin desensitization treatment?

摘要

After completing aspirin desensitization in patients with aspirin-exacerbated respiratory disease (AERD), treatment with daily aspirin in sufficiently large doses (325-1,300 mg/d) has been shown to significantly suppress inflammatory respiratory disease in most patients.1'2 Four clinical observations should be recalled. First, the dose of aspirin that maintains desensitization seems to be independent of the effects of aspirin treatment. For example, 81 mg/d aspirin maintains aspirin desensitization but does not have a measureable effect on disease control. Second, other non-steroidal anti-inflammatory drugs (NSAIDs) can be used to desensitize and maintain desensitization in patients with AERD, but daily treatment with 400 mg of ibuprofen twice daily did not induce therapeutic benefit in 5 patients followed for 1 to 6 months (D. D. S., unpublished data).